Fable Therapeutics Appoints David J. Baker, PhD, as Chief Scientific Officer
Article content
CAMBRIDGE, Mass. — Fable Therapeutics, a discovery-stage biotechnology company developing purpose-built biologics powered by state-of-the-art structure and sequence-based protein language models, today announced the appointment of David J. Baker, PhD, as Chief Scientific Officer (CSO).
Article content
'David's extensive experience in drug discovery, with a strong track record of high performance and scientific leadership across the cardio-metabolic therapeutic area, makes him an ideal leader to advance our portfolio,' said Geoff MacKay, President & CEO of Fable. 'We are excited to welcome David to our leadership team and for him to guide Fable's scientific strategy and innovative platform.'
Article content
Dr. Baker contributes deep expertise leading highly successful teams from across industry and academia. Prior to joining Fable, Dr. Baker was Head of Metabolism Bioscience for Cardiovascular, Renal and Metabolism (CVRM) at AstraZeneca plc. He was responsible for guiding the metabolism portfolio from target selection to Ph2b in diabetes, obesity, MASH and dyslipidemia.
Article content
Dr. Baker joins Fable at a pivotal time to oversee the company's scientific strategy from discovery through to IND and first-in-human studies. 'I'm thrilled to be joining such a groundbreaking company with extremely talented individuals and looking forward to bringing new therapies to patients,' said Dr. Baker.
Article content
About Fable Therapeutics, Inc.
Article content
Fable Therapeutics, Inc. (Fable) is a discovery-stage biotechnology company that aims to improve the lives of the millions of people living with metabolic diseases including obesity and related comorbidities. Founded by veteran biotech entrepreneurs and leading computational scientists and backed by top-tier venture capital firms, Fable is applying an industry-leading sequence- and structure-based machine learning platform to design and optimize next-generation protein-based therapeutics. Fable's pipeline of therapeutics addresses validated target biology that has not yet been fully exploited owing to technical and development hurdles that are addressed by Fable's ML-enabled protein design engine.
Article content
Backed by a 2024 $43.5M Series A investment co-led by Versant Ventures and DCVC, Fable is leading in the purposeful integration of biology and computation to solve complex medical challenges. Fable's aspiration is to write the next chapter of what protein-based therapeutics can do, both through its internal pipeline and research and development partnerships with pharmaceutical companies. Fable has locations in Cambridge, MA and Toronto, Canada.
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
44 minutes ago
- Globe and Mail
Celiac Disease Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Statistics, Revenue, Prevalence, Medication, Treatment Market and Companies by DelveInsight
"Celiac Disease Market" Celiac Disease Companies working in the treatment market are Sanofi (Provention Bio), Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer, 9 Meters Biopharma, Inc., ChemoCentryx, BioLineRx, Ltd., and others (Albany, USA) DelveInsight's 'Celiac Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The Celiac Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Celiac Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Celiac Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Celiac Disease market. To Know in detail about the Celiac Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Some of the key facts of the Celiac Disease Market Report: The Celiac Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In May 2025, Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) today announced that the US Food and Drug Administration (FDA) granted Fast Track designation for investigational TEV-53408, an anti-IL-15 antibody, for the treatment of people with celiac disease on a gluten-free diet. TEV-53408 is currently being evaluated in a Phase 2a trial to assess the efficacy and safety in adults with celiac disease. In March 2025, Barinthus Biotherapeutics plc (NASDAQ: BRNS) has entered 2025 with a renewed strategic focus on immunological and inflammatory diseases. Following its restructuring, the company is well-positioned to advance its lead asset, VTP-1000, along with the SNAP-TI platform, for the treatment of celiac disease. With innovative design features that enhance antigen targeting, allow intramuscular administration, and potentially improve tolerability, VTP-1000 has the potential to become a leading therapy for the approximately 80 million people worldwide affected by celiac disease. In February 2025, PhaseV, a leader in software and machine learning (ML) for clinical trial optimization, announced a strategic partnership with Alimentiv Inc., a global gastrointestinal (GI) contract research organization (CRO). This collaboration aims to enhance the design and execution of advanced adaptive clinical trials for various GI conditions, including inflammatory bowel disease (IBD), celiac disease, eosinophilic gastrointestinal disease (EGID), and other related disorders. In October 2024, Topas Therapeutics reported positive topline results from its Phase IIa trial of TPM502 in celiac disease patients. The findings provide the first clinical proof of concept for the company's proprietary nanoparticle platform, highlighting its potential to induce targeted, antigen-specific tolerogenic effects. In September 2024, Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies that direct T cells to manage diseases, has commenced its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. This randomized, placebo-controlled study, incorporating a controlled gluten challenge, aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTP-1000. In May 2024, Entero Therapeutics, Inc. (previously known as First Wave BioPharma, Inc.) has introduced its new corporate identity and website. This rebranding comes after its recent merger with ImmunogenX and underscores the company's commitment to tackling unmet needs in gastrointestinal health, including celiac disease, a condition that currently lacks approved treatments. In 2023, the United States represented the largest portion of the celiac disease market among the 7MM, contributing roughly 70% to the overall market. Among the EU4 and the UK, Italy had the highest market valuation for celiac disease, estimated at around USD 200 million. At present, a gluten-free diet is the sole effective treatment for celiac disease, with the market in Japan valued at around USD 1,500 million in 2023. Celiac disease exhibits a significant gender imbalance, primarily affecting females. In Germany, for example, around 60% of diagnosed cases are female. In 2023, classical celiac disease accounted for approximately 30% of all celiac disease cases in Japan. According to the Beyond Celiac foundation (2024), approximately 1 in 133 Americans, or around 1% of the population, has celiac disease. It is also estimated that up to 83% of Americans with celiac disease remain undiagnosed or are incorrectly diagnosed with other medical conditions. According to Stahl et al. (2023), Celiac disease is a prevalent chronic condition globally, with an aggregated prevalence of 1.4%, though it can be significantly higher in specific regions. In a prospective birth cohort study involving infants at risk for celiac disease in Europe and the United States, the incidence was estimated to be 3% in Sweden and 2.4% in Colorado. According to the Celiac Disease Foundation, celiac disease is a significant autoimmune disorder estimated to impact 1 in 100 people globally. Additionally, 2.5 million Americans remain undiagnosed and are susceptible to potential long-term health issues. Key Celiac Disease Companies: Sanofi (Provention Bio), Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer, 9 Meters Biopharma, Inc., ChemoCentryx, BioLineRx, Ltd., and others Key Celiac Disease Therapies: PRV-015, TAK-227/ZED1227, Latiglutenase(IMGX003), Ordesekimab, TAK-101 and Zamaglutenase, TPM502, Ritlecitinib, TAK-062, larazotide acetate, CCX282-B, BL-7010, and others The Celiac Disease epidemiology based on gender analyzed that, females are affected more than males The Celiac Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Celiac Disease pipeline products will significantly revolutionize the Celiac Disease market dynamics. Celiac Disease Overview Celiac Disease is a chronic autoimmune disorder triggered by the ingestion of gluten, a protein found in wheat, barley, and rye. Celiac Disease causes an immune response that damages the lining of the small intestine, leading to malabsorption of essential nutrients. Celiac Disease affects both children and adults and can present with a wide range of gastrointestinal and non-gastrointestinal symptoms. Celiac Disease symptoms commonly include abdominal pain, bloating, diarrhea, constipation, fatigue, weight loss, and nutrient deficiencies. Celiac Disease may also manifest through skin rashes, neurological issues, anemia, osteoporosis, and infertility in some individuals. Celiac Disease is strongly associated with genetic factors, particularly the HLA-DQ2 and HLA-DQ8 genes. Celiac Disease diagnosis involves a combination of serologic testing for specific antibodies and confirmation through a small intestinal biopsy. Celiac Disease management requires a strict lifelong gluten-free diet, which helps in healing the intestinal lining and preventing further complications. Celiac Disease patients must avoid even trace amounts of gluten to maintain health and prevent flare-ups. Celiac Disease awareness and early detection are crucial to preventing long-term health consequences. Celiac Disease research continues to explore potential therapies beyond dietary management, including enzyme treatments and immune-modulating agents to improve patient outcomes. Celiac Disease Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Celiac Disease Epidemiology Segmentation: The Celiac Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Population of Celiac Disease in the 7MM Total Diagnosed Prevalent Population of Celiac Disease in the 7MM Type-specific Prevalent Population of Celiac Disease in the 7MM Gender-specific Prevalent Population of Celiac Disease in the 7MM Age-specific Distribution of Celiac Disease in the 7MM Download the report to understand which factors are driving Celiac Disease epidemiology trends @ Celiac Disease Prevalence Celiac Disease Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Celiac Disease market or expected to get launched during the study period. The analysis covers Celiac Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Celiac Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Celiac Disease Therapies and Key Companies PRV-015 : Sanofi (Provention Bio) TAK-227/ZED1227: Zedira, Dr. Falk Pharma, and Takeda Latiglutenase(IMGX003): ImmunoGenX Ordesekimab: Provention Bio/Sanofi TAK-101 and Zamaglutenase: Takeda TPM502: Topas Therapeutics GmbH Ritlecitinib: Pfizer TAK-062: Takeda larazotide acetate: 9 Meters Biopharma, Inc. CCX282- B: ChemoCentryx BL-7010: BioLineRx, Ltd. Discover more about therapies set to grab major Celiac Disease market share @ Celiac Disease Treatment Market Celiac Disease Market Strengths The pipeline activity of Celiac Disease is quite efficient with the presence of variable key players such as First Wave BioPharma, Sanofi, Takeda, etc., which are efficiently involved in developing milestone treatment options. Latiglutenase has the potential to be a first to-market treatment for celiac disease, a GIdisorder that impacts approximately three million people in the US and for which no approved pharmacologic treatment currently exists. Celiac Disease Market Opportunities Several organizations such as Celiac Disease Foundation, National Celiac Association (NCA), American Celiac Disease Alliance (Celiac Disease A), Coelic UK etc. are actively working to provide information and awareness of the disorder. There is ongoing research into celiac disease, including potential treatments and therapies. Individuals with celiac disease can contribute to this research by participating in clinical trials or fundraising for research organizations. Scope of the Celiac Disease Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Celiac Disease Companies: Sanofi (Provention Bio), Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer, 9 Meters Biopharma, Inc., ChemoCentryx, BioLineRx, Ltd., and others Key Celiac Disease Therapies: PRV-015, TAK-227/ZED1227, Latiglutenase(IMGX003), Ordesekimab, TAK-101 and Zamaglutenase, TPM502, Ritlecitinib, TAK-062, larazotide acetate, CCX282-B, BL-7010, and others Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Celiac Disease Unmet Needs, KOL's views, Analyst's views, Celiac Disease Market Access and Reimbursement To know more about Celiac Disease companies working in the treatment market, visit @ Celiac Disease Clinical Trials and Therapeutic Assessment Table of Contents 1. Celiac Disease Market Report Introduction 2. Executive Summary for Celiac Disease 3. SWOT analysis of Celiac Disease 4. Celiac Disease Patient Share (%) Overview at a Glance 5. Celiac Disease Market Overview at a Glance 6. Celiac Disease Disease Background and Overview 7. Celiac Disease Epidemiology and Patient Population 8. Country-Specific Patient Population of Celiac Disease 9. Celiac Disease Current Treatment and Medical Practices 10. Celiac Disease Unmet Needs 11. Celiac Disease Emerging Therapies 12. Celiac Disease Market Outlook 13. Country-Wise Celiac Disease Market Analysis (2020–2034) 14. Celiac Disease Market Access and Reimbursement of Therapies 15. Celiac Disease Market Drivers 16. Celiac Disease Market Barriers 17. Celiac Disease Appendix 18. Celiac Disease Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Globe and Mail
an hour ago
- Globe and Mail
Spinal Muscular Atrophy Pipeline Drugs Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight
"Spinal Muscular Atrophy Pipeline" Spinal Muscular Atrophy companies are Amniotics, Biohaven Pharmaceuticals, Hoffmann-La Roche, Amylon Therapeutics, Voyager Therapeutics, Catalyst Pharmaceuticals, CANbridge Pharmaceuticals Inc., Astellas Pharma, Alcyone Therapeutics, Exicure, AndroScience Corporation, Scholar Rock, NMD Pharma, Aurimed Pharma, Biogen, Hanugen Theraputics, and others. (Albany, USA) 'Spinal Muscular Atrophy Pipeline Insight, 2025″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market. The Spinal Muscular Atrophy clinical trials report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Spinal Muscular Atrophy pipeline constitutes 18+ key companies continuously working towards developing 20+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report: In March 2025, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for people living with spinal muscular atrophy (SMA) who are receiving an SMN-targeted treatment. The FDA will review the application under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2025. The FDA priority review designation conveys that the FDA has determined that if apitegromab is approved, it could offer significant improvement in the safety or effectiveness of treatment of the serious condition of SMA Spinal Muscular Atrophy Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years. Leading Spinal Muscular Atrophy companies working in the market are Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others, are developing therapies for the Spinal Muscular Atrophy treatment Spinal Muscular Atrophy emerging therapies such as – ACTX-401, Apitegromab, GYM329, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years. In February 2025, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) tablet for people living with spinal muscular atrophy (SMA). Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water. In January 2025, Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA). The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA®). On April 2024, Hoffmann-La Roche announced a Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy On April 2024, Genentech announced results of a multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study, if they agree to continue participating in the follow-up assessments. On April 2024, Biogen announced results of a study whose primary objective is to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children's Hospital of Philadelphia-Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score (Part B); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C). On January 2024, Novartis announced results of a Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to < 18 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Discontinued Treatment With Nusinersen (Spinraza®) or Risdiplam (Evrysdi®). On January 2024, NMD Pharma A/S announced results of a Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy On December 2023, Novartis announced results of a Long-term Safety Study in Brazilian Patients With a Confirmed Diagnosis of Spinal Muscular Atrophy (SMA) Treated With Onasemnogene Abeparvovec (Zolgensma®) – ARISER Study. On May 2023, Biogen announced results of a study whose primary objective is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA) Spinal Muscular Atrophy Overview Spinal Muscular Atrophy (SMA) is a rare genetic neuromuscular disorder that affects motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It is caused by mutations in the SMN1 (Survival Motor Neuron 1) gene, which results in reduced levels of the SMN protein essential for motor neuron survival. The severity of SMA varies, and it is classified into different types (SMA 0–4) based on age of onset and disease progression. Spinal Muscular Atrophy primarily affects voluntary muscles, particularly those involved in movement, breathing, and swallowing. Spinal Muscular Atrophy Symptoms range from severe muscle weakness in infancy (SMA Type 1, the most common and severe form) to milder symptoms with later onset (SMA Type 3 and 4). In severe cases, respiratory complications can be life-threatening. Spinal Muscular Atrophy Diagnosis is confirmed through genetic testing. While there is no cure, disease-modifying therapies like nusinersen (Spinraza), risdiplam (Evrysdi), and gene therapy with onasemnogene abeparvovec (Zolgensma) can improve motor function and survival. Supportive care, including physical therapy, respiratory support, and nutritional management, plays a crucial role in improving the quality of life. Spinal Muscular Atrophy Advancements in treatment and early intervention, especially through newborn screening, have significantly improved outcomes for individuals with SMA. Spinal Muscular Atrophy Pipeline Therapeutics Assessment DelveInsight's Spinal Muscular Atrophy Report covers around 20+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include: ACTX-401: Novartis Apitegromab: Scholar Rock GYM329: Roche And Many Others Spinal Muscular Atrophy Pipeline Analysis: The Spinal Muscular Atrophy pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the Spinal Muscular Atrophy treatment with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment. Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies @ Spinal Muscular Atrophy Companies and Drugs Scope of Spinal Muscular Atrophy Pipeline Drug Insight Coverage: Global Key Spinal Muscular Atrophy Companies: Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others Key Spinal Muscular Atrophy Therapies: AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001, BIIB067, and others Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers Table of Contents Spinal Muscular Atrophy Report Introduction Spinal Muscular Atrophy Executive Summary Spinal Muscular Atrophy Overview Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment Spinal Muscular Atrophy Pipeline Therapeutics Spinal Muscular Atrophy Late Stage Products (Phase II/III) Spinal Muscular Atrophy Mid Stage Products (Phase II) Spinal Muscular Atrophy Early Stage Products (Phase I) Spinal Muscular Atrophy Preclinical Stage Products Spinal Muscular Atrophy Therapeutics Assessment Spinal Muscular Atrophy Inactive Products Company-University Collaborations (Licensing/Partnering) Analysis Spinal Muscular Atrophy Key Companies Spinal Muscular Atrophy Key Products Spinal Muscular Atrophy Unmet Needs Spinal Muscular Atrophy Market Drivers and Barriers Spinal Muscular Atrophy Future Perspectives and Conclusion Spinal Muscular Atrophy Analyst Views Appendix About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Globe and Mail
an hour ago
- Globe and Mail
Five Star Bank expands Bay Area presence with new office in Walnut Creek
RANCHO CORDOVA, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Five Star Bancorp (Nasdaq: FSBC) ('Five Star' or the 'Company'), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank, today announced the planned opening of its newest office in Walnut Creek, marking a significant expansion of its Bay Area footprint. 'Fueled by post-pandemic migration and a vibrant small business sector, Walnut Creek has experienced steady commercial growth and rising demand for high-tech and high-touch financial services,' said Executive Vice President / San Francisco Bay Area President, DJ Kurtze. 'With existing client relationships in Walnut Creek — including local favorites like in-coming Original Joe's and Calicraft Brewing Co., — Five Star Bank is seizing the opportunity to provide responsive banking solutions to more East Bay clients.' Five Star Bank's Walnut Creek expansion builds on its broader growth strategy, following the opening of its San Francisco office in September 2024, and demonstrates its commitment to strategic investment in Northern California. The approximately 4,128 square foot, full-service branch will be located at The Plaza at Walnut Creek at 1333 North California Boulevard, Suite 510, in Walnut Creek. The new Walnut Creek office, which is expected to open in the third quarter of 2025, allows Five Star Bank to better serve its growing portfolio of clients in the region, ranging from family-owned businesses to professional service firms shaping the local economy. The space will also accommodate the bank's growing team, with approximately one-third of its Bay Area employees already based in the East Bay. 'We are very pleased to open a new office in Walnut Creek which serves as a natural extension of Five Star Bank's commitment to the dynamic communities of the East Bay,' said Five Star Bank President and Chief Executive Officer, James Beckwith. 'Walnut Creek's thriving business landscape, highly skilled workforce and strong community values make it an ideal location for us to expand our presence. This office enhances our ability to deliver personalized, relationship-based banking while supporting continued growth for our clients and our team. We're proud to invest in a city that reflects the future of the Bay Area.' About Five Star Bancorp Five Star Bancorp is a bank holding company headquartered in Rancho Cordova, California. Five Star operates through its wholly owned banking subsidiary, Five Star Bank. The bank has eight branches in Northern California. For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent plans, estimates, objectives, goals, guidelines, expectations, intentions, projections, and statements of the Company's beliefs concerning future events, business plans, objectives, expected operating results, and the assumptions upon which those statements are based. Forward-looking statements include without limitation, any statement that may predict, forecast, indicate, or imply future results, performance, or achievements, and are typically identified with words such as 'may,' 'could,' 'should,' 'will,' 'would,' 'believe,' 'anticipate,' 'estimate,' 'expect,' 'aim,' 'intend,' 'plan,' or words or phrases of similar meaning. The Company cautions that the forward-looking statements are based largely on the Company's expectations and are subject to a number of known and unknown risks and uncertainties that are subject to change based on factors which are, in many instances, beyond the Company's control. Such forward-looking statements are based on various assumptions (some of which may be beyond the Company's control) and are subject to risks and uncertainties, which change over time, and other factors, which could cause actual results to differ materially from those currently anticipated. New risks and uncertainties may emerge from time to time, and it is not possible for the Company to predict their occurrence or how they will affect the Company. If one or more of the factors affecting the Company's forward-looking information and statements proves incorrect, then the Company's actual results, performance, or achievements could differ materially from those expressed in, or implied by, forward-looking information and statements contained in this press release. Therefore, the Company cautions you not to place undue reliance on the Company's forward-looking information and statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 under the section entitled 'Risk Factors,' and other documents filed by the Company with the Securities and Exchange Commission from time to time. The Company disclaims any duty to revise or update the forward-looking statements, whether written or oral, to reflect actual results or changes in the factors affecting the forward-looking statements, except as specifically required by law. Investor contact Heather C. Luck, Chief Financial Officer Five Star Bancorp (916) 626-5008 hluck@ Media contact Shelley R. Wetton, Chief Marketing Officer Five Star Bancorp (916) 284-7827 swetton@
